News from bionity.com

Evotec completes acquisition of Rigenerand

Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with leading edge in the field of cGMP manufacturing of cell therapies will operate as Evotec (Modena) Srl going forward. Cel...

more…

On the way to cell-type materials

Molecular machines control a sizeable number of fundamental processes in nature. Embedded in a cellular environment, these processes play a central role in the intracellular and intercellular transportation of molecules, as well as in muscle contraction in humans and animals. In order for the entire...

more…

Emerging Omicron subvariants are inhibited less efficiently by antibodies

The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. In many countries, these viruses are now outcompeted by emerging subvariants, with BA.5 being responsible for the current uptick of cases in Germany. However, it is at present largely unclear whet...

more…

Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health

Illumina, Inc. announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health. Illumina Accelerator, located in both San ...

more…

Detection of cancer biomarkers from blood samples using nanopore-based DNA computing technology

Cholangiocarcinoma, also known as bile duct cancer, is a cancer type with a characteristically high mortality. At the time of diagnosis, most bile duct cancers are typically already incurable. This is why methods for the early diagnosis of bile duct cancer are urgently needed. Liquid biopsy, the sam...

more…

Start-up NextImmune supported by Venture Kick

NextImmune, a spin-off from the Biozentrum of the University of Basel, has received financial support of 150,000 Swiss francs from the Venture Kick funding initiative. The start-up develops a new generation of immunosuppressive drugs for autoimmune diseases and organ transplantation. The company Nex...

more…

How bacteria adhere to cells: Basis for the development of a new class of antibiotics

The adhesion of bacteria to host cells is always the first and one of the decisivesteps in the development of infectious diseases. The purpose of this adhesion by infectious pathogens is first to colonize the host organism (i.e., the human body), and then to trigger an infection, which in the worst ...

more…

New PET Hydrolase

Human saliva may contain an enzyme which can decompose the plastic polyethylene terephthalate (PET). Researchers found the promising enzyme, a hydrolase, in a database containing human metagenome samples. As they report in the journal Angewandte Chemie, this newly discovered hydrolase performs bette...

more…

More Brain Lesions in Senior Women than in Men of the Same Age

In women after menopause, the extent of certain brain lesions is larger than in men of the same age. DZNE researchers come to this conclusion based on the assessment of more than 3,400 adults as part of the Bonn Rhineland Study. A team led by neuroscientist Monique Breteler reports on the findings i...

more…

Bacteria for blastoff: Using microbes to make supercharged new rocket fuel

Converting petroleum into fuels involves crude chemistry first invented by humans in the 1800s. Meanwhile, bacteria have been producing carbon-based energy molecules for billions of years. Which do you think is better at the job? Well aware of the advantages biology has to offer, a group of biofuel ...

more…